Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
Holding AUTL?
Track your performance easily
AUTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.06 - $7.45
Previous Close$3.5
Volume1.61M
Average Volume (3M)937.63K
Market Cap
$919.15M
Enterprise Value$275.21M
Total Cash (Recent Filing)$705.94M
Total Debt (Recent Filing)$50.02M
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Nov 12, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding266,094,457
10 Day Avg. Volume1,775,620
30 Day Avg. Volume937,630
Standard Deviation0.24
R-Squared0.19
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.77
Price to Sales (P/S)91.74
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.98
Enterprise Value/Gross Profit162.08
Enterprise Value/Ebitda-2.24
Forecast
1Y Price Target
$8.67Price Target Upside150.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Autolus Therapeutics News
PremiumCompany Announcements
Autolus Therapeutics Highlights Advances at Life Sciences Conference
PremiumCompany Announcements
Autolus Therapeutics Q2 Results and Corporate Presentation Update
PremiumCompany Announcements
Autolus Therapeutics Shares Key FELIX Study UpdatesBulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase I CARLYSLE study of obe-cel in treatment refractory systemic lupus erythematosus (SLE) continues enrollment and is expected to report initial results late 2024, which could be a significant catalyst.
Financial PerformanceAUTL rounded out 2Q24 with $705.9M in cash & equivalents, giving it sufficient runway to obtain data in the first pivotal study in autoimmune as well as the full launch and commercialization of Obe-cel for B-ALL.
Product LaunchThe study highlights durable responses of obe-cel in B-ALL without the need for SCT, suggesting strong potential as a stand-alone therapy.
Bears Say
EfficacyConsolidative SCT post obe-cel did not appear to improve EFS or OS.
Financial PerformanceNet loss per share was higher than consensus indicating a larger than expected financial loss.
Safety ConcernsThere were slightly higher rates of severe CRS/ICANS in patients who received INO.
---
Ownership Overview
― Insiders
14.89% Mutual Funds
0.73% Other Institutional Investors
83.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $3.06 and its highest was $7.45 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Currently, no data Available
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Nov 12, 2024 which is in 8 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Aug 08, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.194 by -$0.026.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -$0.21.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,094,450 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.194. Following the earnings report the stock price went down -9.453%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Among the largest hedge funds holding Autolus Therapeutics Plc’s share is Blackstone Inc.. It holds Autolus Therapeutics Plc’s shares valued at 71M.
---
Autolus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (150.94% Upside)
$8.67 (150.94% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.64%
12-Months-Change
Fundamentals
Return on Equity
-61.80%
Trailing 12-Months
Asset Growth
89.28%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
---
AUTL Company Deck
---
AUTL Earnings Call
Q2 2024
0:00 / 0:00
---
AUTL Stock 12 Month Forecast
Average Price Target
$8.67
▲(150.94% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Bluebird Bio
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering AUTL
1 Year
---